Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France.

Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, "Demonstration of Early Proof-of-Concept for STAR-0310, a Long-Acting OX40 Receptor Antagonist: Initial Safety, PK, and PD Results from a Phase 1a Trial." The presentation will take place at 2:15pm CEST on Wednesday, September 17 th in the Paris Nord room.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.

Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare... Keep Reading...
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy... Keep Reading...
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in... Keep Reading...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive... Keep Reading...
Prismo Metals Announces Results of Shareholder Meeting and Security Based Compensation Grants

Prismo Metals Announces Results of Shareholder Meeting and Security Based Compensation Grants

(TheNewswire) Vancouver, British Columbia, October 2, 2025 TheNewswire - Prismo Metals Inc. (" Prismo " or the " Company ") (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce that all matters were approved at the Company's annual general and special meeting of shareholders held on... Keep Reading...
FPX Nickel Signs Exploration Agreement with Takla Nation for Klow Property

FPX Nickel Signs Exploration Agreement with Takla Nation for Klow Property

FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to announce the signing of an Exploration Agreement (the " Agreement ") with the Takla Nation for exploration activities associated with the Klow property in central British Columbia . The Agreement outlines a... Keep Reading...
Silver47 Completes Successful Red Mountain Drill Program and Intersects Massive Sulfides in Multiple Holes

Silver47 Completes Successful Red Mountain Drill Program and Intersects Massive Sulfides in Multiple Holes

The Red Mountain Deposit Remains Open to Expansion in Multiple Directions with Assays PendingSilver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") is pleased to announce the completion of its summer 2025 drill program at its wholly-owned Red Mountain... Keep Reading...
Redstone Completes Strongly Supported Placement

Redstone Completes Strongly Supported Placement

Redstone Resources Limited (ASX Code: RDS) (‘Redstone’ or the ‘Company’) is pleased to advise that it has received binding commitments for a private placement to professional and sophisticated investors of up to A$650,000 (before costs), exceeding the minimum raising target of $500,000. The... Keep Reading...
Vertex Minerals Limited  2025 Annual Report

Vertex Minerals Limited 2025 Annual Report

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) (OTCMKTS:VTXXF) holds a portfolio of high-grade gold projects in New South Wales and Western Australia, anchored by the flagship Hill End Gold Project. Together with the nearby Hargraves Gold Project, located 35... Keep Reading...
Angkor's Energy Subsidiary Completes 2d Seismic Program On Block VIII Cambodia

Angkor's Energy Subsidiary Completes 2d Seismic Program On Block VIII Cambodia

(TheNewswire) GRANDE PRAIRIE, AB, (September 30, 2025): - TheNewswire - Angkor Resources Corp. (TSXV: ANK and OTC: ANKOF) ("Angkor" or "the Company") announces its energy subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has completed the onshore 350-line kilometer 2D seismic program... Keep Reading...

Latest Press Releases

Related News